FDA Says Medtronic Recalls Implantable Cardioverter-Defibrillators And Cardiac Resynchronization Therapy Defibrillators With Glassed Feedthrough For Risk Of Low Or No Energy Output During High Voltage Therapy; Medtronic Reports 28 Incidents, 22 Injuries, And No Deaths For This Issue
Portfolio Pulse from Benzinga Newsdesk
Medtronic has recalled its Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators due to a risk of low or no energy output during high voltage therapy. The company has reported 28 incidents, 22 injuries, and no deaths related to this issue.
July 18, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Medtronic's recall of its ICDs and Cardiac Resynchronization Therapy Defibrillators could potentially impact its reputation and financial performance.
Recalls often lead to financial losses due to the costs of the recall itself, potential lawsuits, and loss of sales. Additionally, they can damage a company's reputation, which can also lead to a decrease in sales.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100